Cytokinetics Inc financial data

Symbol
CYTK on Nasdaq
Location
350 Oyster Point Boulevard, ., South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 684 % -12.1%
Debt-to-equity -779 % -73.1%
Return On Equity 309 % +57.7%
Return On Assets -45.5 % +18.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares +1.7%
Common Stock, Shares, Outstanding 118M shares +16.3%
Entity Public Float 5.6B USD +180%
Common Stock, Value, Issued 119K USD +1.71%
Weighted Average Number of Shares Outstanding, Basic 119K shares +9.35%
Weighted Average Number of Shares Outstanding, Diluted 119K shares +9.35%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 85.7M USD +2636%
Research and Development Expense 391M USD +18.9%
General and Administrative Expense 242M USD +34.1%
Operating Income (Loss) -547M USD -8.08%
Nonoperating Income (Expense) 58.8M USD +73.4%
Net Income (Loss) Attributable to Parent -606M USD -11.2%
Earnings Per Share, Basic -5 USD/shares +5.03%
Earnings Per Share, Diluted -5 USD/shares +5.03%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 74.9M USD -60.6%
Cash, Cash Equivalents, and Short-term Investments 1B USD -28.6%
Accounts Receivable, after Allowance for Credit Loss, Current 8.41M USD
Assets, Current 887M USD -17%
Property, Plant and Equipment, Net 70.2M USD +6.9%
Operating Lease, Right-of-Use Asset 76.1M USD -1.46%
Other Assets, Noncurrent 14.6M USD +89.5%
Assets 1.23B USD -19.6%
Accounts Payable, Current 16.2M USD +71.4%
Employee-related Liabilities, Current 23.7M USD +18.5%
Accrued Liabilities, Current 52.3M USD +31.4%
Liabilities, Current 131M USD +27.5%
Operating Lease, Liability, Noncurrent 111M USD -4.88%
Other Liabilities, Noncurrent 2.02M USD
Liabilities 1.59B USD +12.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -158K USD +84.5%
Retained Earnings (Accumulated Deficit) -3B USD -25.4%
Stockholders' Equity Attributable to Parent -369M USD -440%
Liabilities and Equity 1.23B USD -19.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -132M USD -1.63%
Net Cash Provided by (Used in) Financing Activities 4.75M USD -95.4%
Net Cash Provided by (Used in) Investing Activities 106M USD +225%
Common Stock, Shares Authorized 163M shares 0%
Common Stock, Shares, Issued 118M shares +16.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -21.2M USD -405%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.6M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 9.65M USD -5.48%
Deferred Tax Assets, Valuation Allowance 713M USD +24.5%
Deferred Tax Assets, Gross 735M USD +23.2%
Operating Lease, Liability 132M USD -4.89%
Payments to Acquire Property, Plant, and Equipment 5.66M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -605M USD -11.1%
Lessee, Operating Lease, Liability, to be Paid 191M USD -8.94%
Property, Plant and Equipment, Gross 103M USD +6.07%
Operating Lease, Liability, Current 19.6M USD +5.83%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20.2M USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.6M USD +4.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 59.4M USD -16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.5M USD +1.66%
Deferred Tax Assets, Operating Loss Carryforwards 283M USD +22%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 31M USD +22.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 20.7M USD +1.09%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.3M USD -1.33%
Share-based Payment Arrangement, Expense 103M USD +21.6%
Interest Expense 11.1M USD -12.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%